Compare Cytokinetics Inc (CYTK) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs JD.Com Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while JD.Com Inc trades at $26.91 (market cap $36.62B). The key difference: JD.Com Inc is far larger — about 4.2× Cytokinetics Inc's market cap, and JD.Com Inc pays a 3.72% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and JD.Com Inc for 85 Days on average.
| CYTK | JD | |
|---|---|---|
Market Cap | $8.62B | $36.62B |
Volume | 2,594,626 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $34.53 |
52-Week Low | $54.76 | $25.19 |
Typical Hold Time | 19 Days | 85 Days |
Enterprise Value | $8.72B | $19.26B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
JD.com is trading at $27.03, up 2.0% today, with strong analyst support showing 32 buy ratings versus just 1 sell. The stock demonstrates solid fundamentals with a low P/E of 17.98 and P/S of 0.2, trading below its $35.86 consensus price target. Recent earnings have consistently beaten expectations, though revenue growth has slowed in 2025 with net income margin declining to 1.13%. The company maintains a robust balance sheet with $234 billion in cash and is pursuing strategic acquisitions including the pending Ceconomy deal.
JD.com presents a compelling value opportunity with significant upside potential to analyst targets, supported by strong cash flow generation and consistent earnings beats. However, investors face risks from slowing revenue growth, regulatory scrutiny of international expansion, and competitive pressures in the Chinese e-commerce sector. The stock's current valuation appears attractive relative to peers, but requires monitoring of execution on strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
